President Donald Trump has issued an executive order aiming to increase domestic production of the controversial weedkiller glyphosate, sold as Roundup.1 Trump’s 18 February order comes under a national security justification for increasing US production of glyphosate for food security. It grants immunity under compliance with the Defense Production Act, which generally protects parties from liability for actions taken to comply with orders under the act, though it does not provide blanket product liability immunity. But the move has brought angry accusations of betrayal from the Make America Healthy Again (MAHA) movement and placed its founder, US health secretary Robert F Kennedy Jr, in the awkward position of defending a product he has long condemned. Roundup is made by Bayer, which acquired the original manufacturer Monsanto in 2018. The pesticide has been the subject of tens of thousands of lawsuits, many from users who claim to have developed non-Hodgkins lymphoma as result of exposure. The move came in the same week Bayer announced a class action settlement over US Roundup claims involving non-Hodgkins lymphoma worth up to $7.25bn (£5.4bn; €6.2bn). The agreement must be confirmed by a court, and lawyers representing about 20 000 plaintiffs who used Roundup at home have objected, arguing that their clients have been offered a fraction of the amount offered to occupational users. Bayer is in what it calls a “multi-pronged strategy to significantly contain the litigation.”2 The company has …